In conclusion, we identified dysregulated expression profiles of LncRNAs and mRNAs in the hippocampus of APP/PS1 mice that may be potential biomarkers or drug targets relevant to the therapeutic effect of DSS on AD. This evidence concerns the gene APP and Alzheimer disease.